by Tim Olmstead | Mar 24, 2022 | Uncategorized
Insights Our Blog Alinea-Group Spotlight Interview: Amar Sharma Amar is a 340B subject matter expert at Alinea Group, and he is currently based in San Diego, CA. He has served in a multitude of roles including medication compliance, 340B Program administration,...
by Tim Olmstead | Feb 24, 2022 | Uncategorized
Insights Our Blog Epic and 340B Relationship Status: It’s Complicated. Blog by Scott Patton My role at The Alinea Group is as a subject matter expert in Epic Willow and Epic 340B reporting. I get to see current implementations as well as help with new ones. My role in...
by Tim Olmstead | Feb 8, 2022 | Uncategorized
Insights Our Blog Strong Statements Decrying Manufacturer Contract Pharmacy Restrictions Highlight The 2022 340B Winter Conference By Magdalena Ordon, 340B Subject Matter Expert | Feb 8, 2022 As hundreds of 340B stakeholders traveled to sunny San Diego this past week...
by Tim Olmstead | Jan 25, 2022 | Uncategorized
Insights Our Blog Crista Parsons Spotlight Welcome Crista L. Parsons, CPhT, MBA We are excited to announce that Crista L. Parsons, CPhT, MBA has joined our team as a Consultant and Subject Matter Expert. Crista comes to Alinea Group with a strong healthcare...
by Tim Olmstead | Jan 12, 2022 | Uncategorized
Insights Our Blog Scott Patton Spotlight At Alinea Group, Scott provides ongoing support, data analytics, pharmacy billing and charge capture. He also works to bring consulting support to various hospital systems through his expertise as an EMR and pharmacy systems...
by Tim Olmstead | Dec 21, 2021 | Uncategorized
Insights Our Blog The Crossroads of 340B and Biosimilars: Challenges and Opportunities If you are a hospital or pharmacy provider, it’s no surprise that the growth of biologic drug spending (14.6%) was more than double the growth of overall drug spending (6.1%)...
